drugset / Trial / NCT05104437
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes
Phase 4
Unknown
1440 enrolled
China National Biotec Group Company Limited
Center for Disease Control and Prevention, Fujian · collabGuizhou Center for Disease Control and Prevention · collabHunan Provincial Center for Disease Control and Prevention · collabWuhan Institute of Biological Products Co., Ltd · collab
Non-randomizedParallel-groupSingle-blindPrevention
Summary
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
Timeline
- Start
- 2021-11
- Primary completion
- 2022-11
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | inactivated SARS-CoV-2 vaccine (Vero Cells) | Vaccine | — | — |